Hormonal Influences on Cancer Progression and Prognosis

Vitamins and Hormones

Volumn 71, Issue , 2005, Pages 147-200

  Sherbet, G V ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; ANDROGEN RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; HORMONE; NUCLEOSIDE DIPHOSPHATE KINASE; NUCLEOSIDE DIPHOSPHATE KINASE A; PROGESTERONE RECEPTOR; PROOPIOMELANOCORTIN; TFF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL; BREAST TUMOR; CANCER INVASION; CELL CYCLE; CELL DIVISION; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; MALE; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; PROSTATE TUMOR; REVIEW;

ALPHA-MSH; ANIMALS; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; ESTROGENS; FEMALE; GENE EXPRESSION; HORMONES; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASMS; NUCLEOSIDE-DIPHOSPHATE KINASE; PRO-OPIOMELANOCORTIN; PROGESTINS; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEINS;

EID: 27744529853     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0083-6729(05)71006-2     Document Type: Review

References (196)

1. Adiga S.K., Andritsch I., Rao R.V., and Krishan A. Androgen receptor expression and DNA content of paraffin-embedded archival human prostate tumours. Cytometry 50 (2002) 25-30
2. Agoff S.N., Swanson P.E., Linden H., Hawes S.E., and Lawton T.J. Androgen receptor expression in estrogen receptor-negative breast cancer-immunohistochemical, clinical, and prognostic associations. Am. J. Clin. Pathol. 120 (2003) 725-731
3. Albini A., Iwamoto Y., Kleinman H.K., Martin G.R., Aaronson S.A., Kozlowski J.M., McEwan R.N., Veilette A., and Lippman M.E. A rapid in vitro assay for quantitating the invasive potential of tumour cells. Cancer Res. 47 (1987) 3239-3245
4. Andronas M., Dlay S.S., and Sherbet G.V. Oestrogen and progesterone receptor expression influences DNA ploidy and the proliferation of breast cancer cells. Anticancer Res. 23 (2003) 3029-3040
5. Angus B., Lennard T.W.J., Naguib R.N.G., and Sherbet G.V. Analysis of molecular prognostic markers in breast cancer by artificial neural networks. In: Naguib R.N.G., and Sherbet G.V. (Eds). "Artificial Neural Networks in Cancer Diagnosis, Prognosis and Patient Management" (2001), CRC Press, Boca Raton, FL 9-21
6. Atanaskova N., Keshamouni V.G., Krueger J.S., Schwartz J.A., Miller F., and Reddy K.B. MAP kinase/oestrogen receptor cross talk enhances oestrogen-mediated signalling and tumour growth but does not confer tamoxifen resistance. Oncogene 21 (2002) 4000-4008
7. Azua J., Romeo P., Serrano M., Tello D.M., and Azua J. Prognostic value from DNA quantification by static cytometry in breast cancer. Anal. Quant. Cytol. Histol. 19 (1997) 80-86
8. Beckler A.D., Roche J.K., Harper J.C., Petroni G., Frierson H.F., Moskaluk C.A., El-Rifai W., and Powell S.M. Decreased abundance of trefoil factor 1 transcript in the majority of gastric carcinomas. Cancer 98 (2003) 2184-2191
9. Benko S., Love J.D., Beladi M., Schwabe J.W.R., and Nagy L. Molecular determinants of the balance between co-repressor and co-activator recruitment to the retinoic acid receptor. J. Biol. Chem. 278 (2003) 43797-43806
10. Bennett D.C., Dexter T.J., Ormerod E.J., and Hart I.R. Increased experimental metastatic capacity of a murine melanoma follows induction of differentiation. Cancer Res. 46 (1986) 3239-3244
11. Berns E.M.J.J., Dirkzwager-Kiel M.J.M., Kuenen-Boumeester V., Timmermans M., Verhoog L.C., van den Ouweland A.M.W., Meijer-Heijboer H., Klijn J.G.M., and van der Kwast T.H. Androgen pathway dysregulation in BRCA1-mutated breast tumours. Breast Cancer Res. Treat. 79 (2003) 121-127
12. Bershtein L.M., Alimova I.N., Tsyrlina E.V., and Anisimov V.N. Mammary tumours in HER-2/NEU mice are characterized by low content of oestrogen receptors-a and absence of progesterone. Bull. Exp. Biol. Med. 135 (2003) 580-581
13. Besse G., Kwiatkowski F., Gaillard G., Daver A., Dalifard I., Basayau J.P., Brunelle P., Wafflart J., Angibeau R.M., and Auvray E. pS2 as a prognostic factor in 1065 cases of human breast cancer. A multicentre study. Bull. Cancer 81 (1994) 289-296
14. Boman K., Maentausta O., Backstrom T., Strang P., and Stendahl U. Sex steroid hormones and receptors in relation to S-phase fraction and ploidy levels in endometrial carcinoma. Anticancer Res. 15 (1995) 999-1002
15. Bonkhoff H., Fixemer T., Hunsicker I., and Remberger K. Progesterone receptor expression in human prostate cancer: Correlation with tumour progression. Prostate 48 (2001) 285-291
16. Bossenmeyer-Pourie C., Kannan R., Ribieras S., Wendling C., Stoll I., Thim L., Tomasetto C., and Rio M.C. The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J. Cell Biol. 157 (2002) 761-770
17. Bostwick D.G., and Burke H.B. Prediction of individual patient outcome in cancer-comparison of artificial neural networks and Kaplan-Meier methods. Cancer 91 (2001) 1643-1646
18. Bregman M.D., Abdel-Malek Z.A., and Meyskens Jr. F.L. Anchorage-independent growth of murine melanoma in serumless media is dependent on insulin or melanocyte stimulating hormone. Exp. Cell Res. 157 (1985) 419-428
19. Brys M., Stawinska M., Foksinski M., Barecki A., Zydek C., Miekos. E., and Krajewska W.M. Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms. Oncol. Rep. 11 (2004) 219-224
20. Campbell M.J., Elstner E., Holden S., Uksodovic M., and Koeffler H.P. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D-2 analogue involves the induction of p21 (waf1), p27 (kip1) and E-cadherin. J. Mol. Endocrinol. 19 (1997) 15-27
21. Campbell R.A., Bhat-Nakshatri P., Patel N.M., Constantinidou D., Ali S., and Nakshatri H. Phosphatidyl inositol 3-kinase/Akt-mediated activation of oestrogen receptor alpha. A new model for anti-oestrogen resistance. J. Biol. Chem. 276 (2001) 9817-9824
22. Canton I., Eves P.C., Szabo M., Vidal-Vanaclocha F., Sisley K., Rennie I.G., Haycock J.W., and MacNeil S. Tumour necrosis factor alpha increases and alpha-melanocyte-stimulating hormone reduces uveal melanoma invasion through fibronectin. J. Invest. Dermatol. 121 (2003) 557-563
23. Carlsberg C., and Polly P. Gene regulation by vitamin D3. Crit. Rev. Eukaryotic Gene Expression 8 (1998) 19-42
24. Carvalho R., Kayademir T., Soares P., Canedo P., Sousa S., Oliveira C., Leistenschneider P., Seruca R., Gott P., Blin N., Carneiro F., and Machado J.C. Loss of heterozygosity and promoter methylation, but not mutation, may underlie loss of TFF1 in gastric carcinoma. Lab. Invest. 82 (2002) 1319-1326
25. Chakraborty A.K., Funasaka Y., Ichihashi M., Sodi S., Bhattacharya M., and Pawelek J. Up regulation of mRNA for the melanocortin-1 receptor but not for melanogenic proteins in macrophage x melanoma fusion hybrids exhibiting increased melanogenic and metastatic potential. Pigment Cell Res. 2 (1999) 355-366
26. Chariot A., and Castronovo V. Detection of HOX-A1 expression in human breast cancer. Biochem. Biophys. Res. Commun. 222 (1996) 292-297
27. Chevallier B., Heintzmann F., Mosseri V., Dauce J.P., Bastit P., Graic Y., Brunellke P., Basayau J.P., Comozm M., and Asselain B. Prognostic value of oestrogen and progesterone receptors in operable breast cancer-results of a univariate and multivariate analysis. Cancer 62 (1988) 2517-2524
28. Christensen J.G., Schreck R., Burrows J., Kuruganti P., Chan E., Le P., Chen J., Wang X.Y., Ruslim L., Blake R., Lipson K.E., Ramphal J., Do S., Cui J.R.J., Cherrington J.M., and Mendel D.B. A selective small molecular inhibitor of c-met kinase inhibits c-met-dependent phenotypes in vitro and exhibits cytoreductive anti-tumour activity in vivo. Cancer Res. 63 (2003) 7345-7355
29. Christoffers A.B., Kreisler M., and Willershausen B. Effects of oestradiol and progesterone on the proliferation of human gingival fibroblasts. Eur. J. Med. Res. 8 (2003) 535-542
30. Clark G.M., McGuire W.I., Hubay C.A., Pearson O.H., and Marshall J.S. Progesterone receptors as a prognostic factor in stage II breast cancer. N. Engl. J. Med. 309 (1983) 1343-1347
31. Cui X.J., Lazard Z., Zhang P., Hopp T.A., and Lee A.V. Progesterone cross talks with insulin-like growth factor signalling in breast cancer cells via induction of insulin receptor substrate-2. Oncogene 22 (2003) 6937-6941
32. Debes J.D., Sebo T.J., Lohse C.M., Murphy L.M., Haugen D.L., and Tindall D.J. P300 in prostate cancer proliferation and progression. Cancer Res. 63 (2003) 7638-7640
33. Deftos L.J. Granin-A, parathyroid hormone-related protein, and calcitonin gene products in neuroendocrine prostate cancer. Prostate 8 (1998) 23-31
34. Deng L., Shipley G.L., Loose-Mitchell D.S., Stancel G.M., Broaddus R., Pickar J.H., and Davies P.J.A. Coordinate regulation of the production and signalling of retinoic acid by oestrogen in the human endometrium. J. Clin. Endocrinol. Metab. 88 (2003) 2157-2163
35. Depowski P.L., Rosenthal S.I., and Ross J.S. Loss of expression of PTEN gene protein is associated with poor outcome in breast cancer. Modern Pathol. 14 (2001) 672-676
36. Di Nezza L.A., Jobling T., and Salamonsen L.A. Progestin suppresses matrix metalloproteinase production in endometrial cancer. Gynecol. Oncol. 89 (2003) 325-333
37. Djavan B., Remzi M., Zlotta A., Seitz C., Snow P., and Marberger M. Novel artificial neural network for early detection of prostate cancer. J. Clin. Oncol. 20 (2002) 921-929
38. Elia G., Ren Y., Lorenzoni P., Zarnegar R., Burger M.M., and Rusciano D. Mechanisms regulating c-met over-expression in liver metastatic B16-LS9 melanoma cells. J. Cell. Biochem. 81 (2001) 477-487
39. Elkin M., Cohen I., Zcharia E., Orgel A., Guatta-Rangini Z., Peretz T., Vlodavsky I., and Kleinman H.K. Regulation of heparanase gene expression by oestrogen in breast cancer. Cancer Res. 63 (2003) 8821-8826
40. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grades in breast cancer. Experience from a large study with long-term follow up. Histopathology 19 (1991) 403-410
41. Esteva J., Bellotti M., and Marchevsky. A.M. Neural networks for the estimation of prognosis in lung cancer. In: Naguib R.N.G., and Sherbet G.V. (Eds). "Artificial Neural Networks in Cancer Diagnosis, Prognosis and Patient Maagement" (2001), CRC Press, Boca Raton, FL 27-35
42. Eves P., Haycock J., Layton C., Wagner M., Kemp H., Szabo M., Morandini R., Ghanem G., Garcia-Borron J.C., Jimenez-Cervantes C., and MacNeil S. Anti-inflammatory and anti-invasive effects of alpha-melanocyte-stimulating hormone in human melanoma cells. Br. J. Cancer 89 (2003) 2004-2015
43. Falette N.S., Fuqua S.A., Chamness G.C., Cheah M.S., Greene G.L., and McGuire W.L. Oestrogen receptor gene methylation in human breast tumours. Cancer Res. 50 (1990) 3874-3978
44. Fan S., Wang J.A., Yuan R., Ma Y., Meng Q., Erdos M.R., Pestell R.G., Fang Y., Auborn K.J., Goldberg I.D., and Rosen E.M. BRCA1 inhibition of oestrogen receptor signalling in transfected cells. Science 284 (1999) 1354-1356
45. Ferro P., Catalano M.G., Dell'Eva R., Fortunati N., and Pfeffer U. The androgen receptor CAG repeat. A modifier of carcinogenesis?. Mol. Cell. Endocrinol. 193 (2002) 109-120
46. Fisher B., Ravdin R.G., Ausman R.K., Slack B.N.H., Moore G.E., and Noer R.J. Surgical adjuvant chemotherapy in cancer of the breast: Results of a decade cooperative investigation. Ann. Surg. 168 (1996) 337-356
47. Frasor J., Danes J.M., Komm B., Chang K.C.N., Lyttle C.R., and Katzenellenbogen B.S. Profiling of oestrogen up- and down-regulated gene expression in human breast cancer cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144 (2003) 4362-4574
48. Galea M.H., Blamey R.W., Elston C.E., and Ellis I.O. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res. Treat. 22 (1992) 207-219
49. Ghosh P.M., Malik S., Bedolla R., and Kreisberg J.I. Akt in prostate cancer: Possible role in androgen-independence. Curr. Drug Metab. 4 (2003) 487-496
50. Gilchrist K.W., Gray R., Vandrielkulker A.M.J., Mesker W.E., Ploem-Zaaijer J.J., Ploem J.S., Taylor S.G., and Rormey D.C. High DNA content and prognosis in lymph node positive breast cancer. A case control study by the University of Leiden and ECOG. Breast Cancer Res. Treat. 28 (1993) 1-8
51. Gillesby B.E., and Zacharewski T.R. pS2 (TFF1) levels in human breast cancer tumour samples: Correlation with clinical and histological prognostic markers. Breast Cancer Res. Treat. 56 (1999) 253-265
52. Giovannucci E., Stampfer M.J., Krithivas K., Brown M., Dahl D., Brufsky A., Talcott J., Hennekens C.H., and Kantoff P.W. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. USA 94 (1997) 3320-3323
53. Greenberg R., Schwartz I., Skornick Y., and Kaplan O. Detection of hepatocyte growth factor/scatter factor receptor (c-met) in axillary drainage after operations for breast cancer using reverse transcriptase polymerase chain reaction. Breast Cancer Res. 5 (2003) R71-R76
54. Grey S.R., Dlay S.S., and Sherbet G.V. The role of artificial neural networks and fuzzy systems in disease assessment and patient management. J. Quality Life Res. 1 (2003) 321-334
55. Grey S.R., Dlay S.S., and Sherbet G.V. Prediction of nodal spread of breast cancer by artificial neural network-based analyses of S100A4, nm23 and steroid receptor expression. Clin. Exp. Metastasis 20 (2003) 507-514
56. Gudas J.M., Nguyen H., Li T., and Cowan K.H. Hormone dependent regulation of BRCA1 in human breast cancer cells. Cancer Res. 55 (1995) 4561-4565
57. Guzeloglu-Kayisli O., Kayisli U.A., Al-Rejjal R., Zheng W.X., Luleci G., and Arici A. Regulation of PTEN (phosphatase and tensin homologue deleted on chromosome 10) expression by oestradiol and progesterone in human endometrium. J. Clin. Endocrinol. Metabol. 88 (2003) 5017-5026
58. Hackel C., Falkenberg B., Gunther T., Lippert H., and Roessner A. The pS2 protein in colorectal carcinomas and metastases. Pathol. Res. Pract. 194 (1998) 171-176
59. Halaban R. The regulation of normal melanocyte proliferation. Pigment Cell Res. 13 (2000) 4-14
60. Hallouche F., Adams A.E., Hinton O., Relf G., Lakshmi M.S., and Sherbet G.V. Image processing for cell cycle analysis and discrimination in metastatic variant cell lines of the B16 melanoma. Pathobiology 60 (1992) 76-81
61. Hawkins R.A., Roberts M.M., and Forrest A.P.M. Oestrogen receptors and breast cancer: Current status. Br. J. Surg. 67 (1980) 53-169
62. Hawkins R.A., Tesdale A.L., Prescott R.J., Forster T., McIntyre M.A., Baker P., Jack W.J.L., Chetty U., Dixon J.M., Killen M.E., Hulme M.J., and Miller W.R. Outcome after extended follow-up in a prospective study of operable breast cancer: Key factors and a prognostic index. Br. J. Cancer 87 (2002) 8-14
63. Hearle N., Humphreys J., Damato B.E., Wort R., Talaban R., Wixey J., Green H., Easton D.F., and Houlston R.S. Role of MC1R variants in uveal melanoma. Br. J. Cancer 89 (2003) 1961-1965
64. Hinton D.R., Hahn J.A., Weiss M.H., and Couldwell W.T. Loss of RB expression in an ACTH-secreting pituitary carcinoma. Cancer Lett. 126 (1998) 209-214
65. Hong J.T., Shah N.N., Thomas T.J., Gallo M.A., Yurkow E.J., and Thomas T. Differential effects of oestradiol and its analogues on cyclin D1 and CDK4 expression in oestrogen receptor positive MCF-7 and oestrogen receptor-transfected MCF-10AE (wt5) cells. Oncol. Rep. 5 (1998) 1025-1033
66. Horiguchi J., Koibuchi Y., Iijima K., Yoshida T., Yoshida M., Takata D., Oyama T., Iino Y., and Morishita Y. Immunohistochemical double staining with oestrogen receptor and HER2 on primary breast cancer. Int. J. Mol. Med. 12 (2003) 855-859
67. Hsia T.C., Chiang H.C., Chiang D., Hang L.W., Tsai F.J., and Chen W.C. Prediction of survival in surgical unresectable lung cancer by artificial neural networks including genetic polymorphisms and clinical parameters. J. Clin. Lab. Anal. 17 (2003) 229-234
68. Hu X.L., Chen Y.X., Farooqui M., Thomas M.C., Chiang C.M., and Wei L.N. Suppressive effect of receptor-interacting protein 140 on co-regulator binding to retinoic acid receptor complexes, histone-modifying enzyme activity, and gene activation. J. Biol. Chem. 279 (2004) 319-332
69. Ingles S.A., Ross R.K., Yu M.C., Irvine R.A., La Pera G., Haile R.W., and Coetzee G.A. Association of prostate cancer risk with genetic polymorphisms in vitamin D3 receptor and androgen receptor. J. Natl. Cancer Inst. 89 (1997) 166-170
70. Ioakin-Liossi A., Karakitsos P., Markopoulos C., Aaroni K., Delivelioti K., Gogas J., and Kyrkou K. Expression of pS2 and oestrogen and progesterone receptor status in breast cancer. Acta Cytol. 41 (2003) 713-716
71. Issa J.J., Baylin S.B., and Belinsky S.A. Methylation of oestrogen receptor CpG island in lung cancer is related to the specific types of carcinogen exposure. Cancer Res. 56 (1998) 3655-3658
72. Issa J.J., Ottaviano Y.L., Celano P., Hamilton S.R., Davidson N.E., and Baylin S.B. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat. Genet. 7 (1994) 536-540
73. Issa J.J., Zehnbauer B.A., Civin C.I., Collector M.J., Sharkis S.J., Davidson N.E., Kaufmannn S.H., and Baylin S.B. The oestrogen receptor CpG island is methylated in most haematopoietic neoplasms. Cancer Res. 56 (1996) 973-977
74. Jensen R.A., Thompson M.E., Jetton T.L., Szabo C.I., van der Meer R., Helou B., Tronick S.R., Page D.L., King M.C., and Holt J.T. BRCA1 is secreted and exhibits properties of a granin. Nat. Genet. 12 (1996) 303-308
75. Kadekaro A.L., Kanto H., Kavanagh R., and Abdel-Malek Z.A. Significance of the melanocortin 1 receptor in regulating human melanocyte pigmentation, proliferation, and survival. Ann. N.Y. Acad. Sci. 994 (2003) 359-365
76. Kappes H., Goemann C., Bamberger A.M., Loning T., and Milde-Langosch K. PTEN expression in breast and endometrial cancer. Correlation with steroid hormone receptor status. Pathobiology 69 (2001) 136-142
77. Kimura F., Watanabe J., Hata H., Fujisawa T., Kamata Y., Nishimura Y., Jobo T., and Kuramoto H. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J. Cancer Res. Clin. Oncol. 130 (2004) 161-168
78. Koshiyama M., Yoshida M., Konishi M., Takemura M., Yura Y., Matsushita K., Hayashi M., and Tauchi K. Expression of pS2 protein in endometrial carcinomas: Correlation with clinicopathologic features and sex steroid receptor status. Int. J. Cancer 74 (1997) 237-244
79. Lakhani S.R., van de Vijver M.J., Jacquemier J., Anderson T.J., Osin P.P., McGuffog L., and Easton D.F. The pathology of familial breast cancer: Predictive value of immunohistochemical markers oestrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol. 20 (2002) 2310-2318
80. Lakshmi M.S., and Sherbet G.V. Measurement of DNA content and nuclear pleomorphism in metastatic variants of the B16 murine melanoma and hamster lymphoma and its liver metastases using image analysis techniques. Clin. Exptl. Metastasis 8 (1990) 553-566
81. Lakshmi M.S., and Sherbet G.V. Expression of transmembrane glycoprotein CD44 and metastasis associated gene 18A2/mts1 gene in B16 murine melanoma. Anticancer Res. 17 (1997) 3451-3456
82. Lakshmi M.S., Parker C., and Sherbet G.V. Metastasis associated mts1 and nm23 genes affect tubulin polymerisation in B16 melanomas: A possible mechanism of their regulation of metastatic behaviour of tumours. Anticancer Res. 13 (1993) 299-304
83. Langner C., Ratschek M., Rehak P., Schips L., and Zigeuner R. Steroid hormone receptor expression in renal cell carcinoma: An immunohistochemical analysis of 182 tumours. J. Urol. 171 (2004) 611-614
84. Lapidus R.G., Ferguson A.T., Ottaviano Y.L., Parl F.F., Smith H.S., Weitzman S.A., Baylin S.B., Issa J.P.J., and Davidson N.E. Methylation of oestrogen and progesterone receptor gene 5′ CpG islands correlates with lack of oestrogen and progesterone receptor gene expression in breast tumours. Clin. Cancer Res. 2 (1996) 805-810
85. Latta E., and Chapman W.B. PTEN mutations and evolving concepts in endometrial neoplasia. Curr. Opin. Obstet. Gynecol. 14 (2002) 59-65
86. Lee S.O., Lou W., Hou M., Onate S.A., and Gao A.C. Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene 22 (2003) 7981-7988
87. Leers M.P.G., Schutte B., Theunissen P.H.M.H., Ramaekers F.C.S., and Nap M. A novel flow cytometric steroid hormone receptor assay for paraffin-embedded breast carcinoma. An objective quantification of the steroid hormone receptors and direct correlation to ploidy status and proliferative capacity in a single tube assay. Human Pathol. 31 (2000) 584-592
88. Lewis J.S., Thomas T.J., Klinge C.M., Gallo M.A., and Thomas T. Regulation of cell cycle and cyclins by 16 alpha-hydroxyestrone in MCF-7 breast cancer cells. Mol. Endocrinol. 27 (2001) 293-307
89. Li L.C., Chui K., Nakajima K., Oh B.R., Au H.C., and Dahiya R. Frequent methylation of oestrogen receptor in prostate cancer. Correlation with tumour progression. Cancer Res. 60 (2000) 702-706
90. Li P.F., Nicosai S.V., and Bai W.L. Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cells. J. Biol. Chem. 276 (2001) 20444-20450
91. Lin K.H., Wang W.J., Wu Y.H., and Cheng S.Y. Activation of anti-metastatic Nm23-H1 gene expression by oestrogen and its alpha-receptor. Endocrinology 143 (2002) 467-475
92. Lin V.C.L., Eng A.S., Hen N.E., Ng E.H.L., and Chowdhury S.H. Effect of progesterone on the invasive properties and tumour growth of progesterone receptor-transfected breast cancer cells MDA-MB-231. Clin. Cancer Res. 7 (2001) 2880-2886
93. Linjawi A., Kontogiannea M., Halwani F., Edwardes M., and Meterissian S. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. Am. Coll. Surg. 198 (2004) 83-90
94. Looi L.M., Azura W.W., Chah P.L., and Ng M.H. PS2 expression in infiltrating ductal carcinoma of the breast correlates with oestrogen receptor positivity but not with histological grade and lymph node status. Pathology 33 (2001) 283-286
95. Lu D., Kiriyama Y., Lee K.Y., and Giguere V. Transcriptional regulation of the oestrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors. Cancer Res. 61 (2001) 6755-6761
96. Lunec J., Pieron C., Sherbet G.V., and Thody A.J. Alpha melanocyte stimulating hormone immunoreactivity in melanoma cells. Pathobiology 58 (1990) 193-197
97. Luqmani Y., Temmim L., Memon A., Parkar A., Ali M., Motawy M., and Baker H. Immuno-radiometric measurement of pS2 in breast cancer. Correlation with steroid receptors and plasminogen activators. Acta Oncol. 38 (1999) 805-914
98. Maggiora P., Marchio S., Stella M.C., Giai M., Belfiore A., De Bartoli M., Di Renzo M.F., Constitino A., Sismondi P., and Comoglio P.M. Over-expression of the RON gene in human breast carcinoma. Oncogene 16 (1998) 2927-2933
99. Mannweiler S., Tsybrovskyy O., and Regauer S. The flow cytometric DNA index can predict the presence of lymph node metastases in invasive ductal breast carcinoma. APMIS 110 (2002) 580-586
100. Marino M., Acconcia F., and Trentalance A. Biophasic oestradiol-induced Akt phosphorylation is modulated by PTEN via MAP kinase in HepG2 cells. Mol. Biol. Cell 14 (2003) 2583-2591
101. Mars W.M., Zarnegar R., and Michalopoulos G.K. Activation of hepatocyte growth factor by the plasminogen activator uPA and tPA. Am. J. Pathol. 143 (1993) 949-958
102. Martin V., Ribieras S., Song-Wang X.G., Lasne Y., Frappart L., Rio M.C., and Dante R. Involvement of DNA methylation in the control of the expression of an oestrogen-induced breast-cancer-associated protein (pS2) in human breast cancers. J. Cell Biochem. 65 (1997) 95-106
103. Mason B.H., Holdaway I.M., Mullins P.R., Yee L.H., and Kay R.G. Progesterone and oestrogen receptors as prognostic variables in breast cancer. Cancer Res. 43 (1983) 2985-2990
104. Matsumoto T., Sowa Y., Ohtani-Fujita N., Tamaki T., Takenaka T., Kuribayashi K., and Sakai T. P53-independent induction of Waf1/cip1 is correlated with osteoblastic differentiation of vitamin D-3. Cancer Lett. 129 (1998) 61-68
105. Michels J.J., Duigou F., Marnay J., Denoux Y., Delozier T., and Chasle J. Flow cytometry in primary breast carcinomas: Prognostic impact of multiploidy and hypoploidy. Cytometry [Clin] 55B (2003) 37-45
106. Mizumoto H., Saito T., Ashihara K., Nishimura M., Tanaka R., and Kudo R. Acceleration of invasive activity via matrix metalloproteinases by transfection of the oestrogen receptor-alpha gene in endometrial carcinoma cells. Int. J. Cancer 100 (2002) 401-406
107. Muller P., Kietz S., Gustafsson J.A., and Strom A. The anti-estrogenic effect of all-trans-retinoic acid on the breast cancer cell line MCF-7 is dependent on HES-1 expression. J. Biol. Chem. 277 (2002) 28376-28379
108. Murata J., Ayukawa K., Ogasawara M., Fujii H., and Saiki I. Alpha-melanocyte-stimulating hormone blocks invasion of reconstituted basement membrane (Matrigel) by murine B16 melanoma cells. Invasion Metastasis 17 (1997) 82-93
109. Naguib R.N.G., Mat-Sakim H.A., Lakshmi M.S., Wadehra V., Lennard T.W.J., Bhatavdekar J., and Sherbet G.V. DNA ploidy and cell cycle distribution of breast cancer fine needle aspirate cells analysed by image cytometry and neural networks. Anticancer Res. 17 (1997) 4046-4047
110. Naguib R.N.G., Mat-Sakim H.A., Lakshmi M.S., Wadehra V., Lennard T.W.J., Bhatavdekar J.M., and Sherbet G.V. DNA ploidy and cell cycle distribution of breast cancer aspirate cells measured by image cytometry and analysed by artificial neural networks for their prognostic significance. Trans. Inform. Tech. Biomed. 3 (1999) 61-69
111. Naguib R.N.G., and Sherbet G.V. Artificial neural approach to analysing the prognostic significance of DNA ploidy and cell cycle distribution of breast cancer aspirate cells. In: Naguib R.N.G., and Sherbet G.V. (Eds). "Artificial Neural Networks in Cancer Diagnosis, Prognosis and Patient Management" (2001), CRC Press, Boca Raton, FL 23-27
112. Nunez J., Berry J., Imler J.L., and Chambon P. The 5′-flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogen, epidermal growth factor, a tumour promoter (TPA), the c-Ha-Ras oncoprotein and the c-jun protein. EMBO J. 8 (1989) 823-829
113. Oates A.J., Barraclough R., and Rudland P.S. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 13 (1996) 97-104
114. Oates A.J., Barraclough R., and Rudland P.S. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 17 (1997) 1-15
115. Osborne C.K., and Schiff R. Growth factor receptor cross talk with oestrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 12 (2003) 362-367
116. Osin P., Gusterson B.A., Philp E., Waller J., Bartek J., Peto J., and Crook T. Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. Eur. J. Cancer 34 (1998) 1683-1686
117. Ottaviano Y.L., Issa J.J., Parl F.F., Smith H.S., Baylin S.B., and Davidson N.E. Methylation of the oestrogen receptor gene CpG island marks loss of oestrogen receptor expression in human breast cancer cells. Cancer Res. 54 (1994) 2552-2555
118. Ottesen G.L., Christensen I.J., Larsen J.K., Larsen J., Baldetorp B., Linden T., Hansen B., and Andersen J. Carcinoma in situ of the breast: Correlation of histopathology to immunohistochemical markers and DNA ploidy. Breast Cancer Res. Treat. 60 (2000) 219-226
119. Peace B.E., Hughes M.J., Degen S.J.F., and Waltz S.E. Point mutations and over expression of Ron induce transformation, tumour formation, and metastasis. Oncogene 20 (2001) 6142-6151
120. Pereda M.P., Lohrer P., Kovalovsky D., Castro C.P., Goldberg V., Losa M., Chervin A., Berner S., Molina H., Stalla G.K., Renner U., and Arzt E. Interleukin-6 is inhibited by glucocorticoids and stimulates ACTH secretion and POMC expression in human corticotroph pituitary adenomas. Exp. Clin. Endocrinol. Diabetes 108 (2000) 202-207
121. Perren A., Weng L.P., Boag A.H., Ziebold U., Thakore K., Dahia P.L.M., Komminoth P., Lees J.A., Mulligan L.M., Mutter G.L., and Eng C. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol. 455 (1999) 1253-1260
122. Phippard D.J., Weber-Hall S.J., Sharpe P.T., Naylor M.S., Jayatalake H., Maas R., Woo I., Roberts-Clark D., Francis-West P.H., Liu Y.H., Maxson R., Hill R.E., and Dale T.C. Regulation of Msx-1, Msx-2, Bmp-2, and Bmp-4 during foetal a postnatal mammary gland development. Development 122 (1996) 2729-2737
123. Pinto A.E., Andre S., Mendonca E., Silva G., and Soares J. Overall survival in advanced breast cancer: Relevance of progesterone receptor expression and DNA ploidy in fine-needle aspirates of 392 patients. Int. J. Biol. Markers 18 (2003) 7-12
124. Pinto A.E., Andre S., Pereira T., Nobrega S., and Soares J. C-erbB-2 oncoprotein over expression identifies a subgroup of oestrogen receptor positive (ER+) breast cancer patients with poor prognosis. Ann. Oncol. 12 (2001) 525-533
125. Piva R., Kumar V.L., Hanau S., Rimondi A.P., Pansini S., Mollica G., and Delsenno L. Abnormal methylation of oestrogen receptor gene and reduced oestrogen receptor RNA levels in human endometrial carcinomas. J. Steroid Biochem. Mol. Biol. 32 (1989) 1-4
126. Piva R., Rimondi A.P., Hanau S., Maestri I., Alvisi A., Kumar V.L., and Delsenno L. Different methylation of oestrogen receptor DNA in human breast carcinomas with and without oestrogen receptor. Br. J. Cancer 61 (1990) 270-275
127. Polly P., Carlsberg C., Eisman J.A., and Morrison N.A. Identification of a vitamin D-3 response element in the fibronectin gene that is bound by a vitamin D-3 receptor homodimer. J. Cell. Biochem. 60 (1996) 322-333
128. Prest S.J., May F.E.B., and Westley B.R. The oestrogen-regulated protein TFF1 stimulates migration of human breast cancer cells. FASEB J. 16 (2002) U252-U271
129. Prins G.S., Chang W.Y., Wang Y., and van Breeman R.B. Retinoic acid receptors and retinoids are up-regulated in the developing and adult rat prostate by neonatal estrogen exposure. Endocrinology 143 (2002) 3628-3640
130. Qiu M., and Lange C.A. MAP kinases couple multiple functions of human progesterone receptors: Degradation, transcriptional synergy, and nuclear association. J. Steroid Biochem. Mol. Biol. 85 (2003) 147-157
131. Rayter Z. Steroid receptors in breast cancer. Br. J. Surg. 78 (1991) 528-535
132. Rio M.C., Bellocq J.P., Gairard B., Koehl C., Renaud R., and Chambon P. Specific expression of human pS2 gene in breast cancer. Biochemie 70 (1988) 961-968
133. Rio M.C. What is/are the function(s) of trefoil peptides. Bull. Cancer 84 (1997) 443-446
134. Rio M.C., Bellocq J.P., Daniel J.Y., Tamasetto C., Lathe R., Chennard M.P., Baezenschlager A., and Chambon P. Breast cancer associated pS2 protein: Synthesis and secretion by normal stomach mucosa. Science 241 (1988) 705-708
135. Robinson E.K., Grau A.M., Evans D.B., Smid C.M., Chiao P.J., Abbruzzese J.L., and Grimm E.A. Cell cycle regulation of human pancreatic cancer by tamoxifen. Ann. Surg. Oncol. 5 (1998) 342-349
136. Robinson S.J., and Healy E. Human melanocortin 1 receptor (MC1R) gene variants alter melanoma cell growth and adhesion to extracellular matrix. Oncogene 21 (2002) 8037-8046
137. Rodrigues S., Attoub S., Nguyen Q.D., Bruyneel E., Rodrigue C.M., Westley B.R., May F.E.B., Thim L., Mareel M., Emami S., and Gespach C. Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signalling pathways in kidney and colonic cancer cells. Oncogene 22 (2003) 4466-4497
138. Rousseau C., Pettersson F., Couture M.C., Paquin A., Galipeau J., Mader S., and Miller W.H. The N-terminal of the oestrogen receptor (ER alpha) mediates transcriptional cross talk with the retinoic acid receptor in human breast cancer cells. Steroid Biochem. Mol. Biol. 86 (2003) 1-14
139. Rusciano D. Differentiation and metastasis in melanoma. Critical Rev. Oncol. 11 (2000) 147-163
140. Rusciano D., Lorenzone P., Lin S., and Burger M.M. Hepatocyte growth factor scatter factor and hepatocytes are potent down regulators of tyrosinase expression in B16 melanoma cells. J. Cell. Biochem. 71 (1998) 264-276
141. Rusciano D., Lorenzoni P., and Burger M.M. Regulation of c-met expression in B16 murine melanoma cells by melanocyte stimulating hormone. J. Cell Sci. 112 (1999) 620-633
142. Sagol O., Tuna B., Coker A., Karademir S., Obuz F., Astarcioglu H., Kupelioglu A., Astarcioglu I., and Topalak O. Immunohistochemical detection of PS2 protein and heat shock protein-70 in pancreatic adenocarcinomas. Relationship with disease extent and patient survival. Pathol. Res. Practice 198 (2002) 77-84
143. Santoro M.M., Penengo L., Minetto M., Orecchia S., Cilli M., and Gaudino G. Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor. Oncogene 17 (1998) 741-749
144. Schmitt F.C. Multistep progression from an oestrogen-dependent growth towards an autonomous growth in breast carcinogenesis. Eur. J. Cancer 31A (1995) 2049-2052
145. Seker H., Odetayo M., Petrovic D., Naguib R.N.G., Bartoli C., Alasio L., Lakshmi M.S., and Sherbet G.V. Assessment of nodal involvement and survival analysis in breast cancer patients using image cytometric data: Statistical, neural network and fuzzy approaches. Anticancer Res. 22 (2002) 433-438
146. Shen X.L., and Falzon M. Parathyroid hormone-related protein up regulates integrin expression via an intracrine pathway in PC-3 prostate cancer cells. Regulatory Peptides 113 (2003) 17-29
147. Sherbet G.V. "The Biology of Tumour Malignancy." (1982), Academic Press, London
148. Sherbet G.V. "Calcium Signalling in Cancer: The Role of Calcium Binding Proteins in Cell Proliferation, Invasion and Metastasis." (2001), CRC Press, Boca Raton, FL
149. Sherbet G.V. "Genetic Recombination in Cancer." (2003), Academic Press/Elsevier, London
150. Sherbet G.V., and Lakshmi M.S. Measurement of DNA content and nuclear pleomorphism using image analysis techniques. Clin. Exptl. Metastasis 8 (1990) 34
151. Sherbet G.V., and Lakshmi M.S. "The Genetics of Cancer: Genes Associated with Cancer Invasion, Metastasis and Cell Proliferation." (1997), Academic Press, London
152. Sherbet G.V., and Patil D. Molecular progression of ovarian cancer. In: Sherbet G.V. (Ed). "Molecular and Cellular Pathology of Cancer Progression and Prognosis" (2005), Transworld Research Network, Trivandrum
153. Shiozaki H., Kadowsaki T., Doki Y., Inoue M., Tamuraa S., Oka H., Iwagawa T., Matsui S., Shimaya K., Takeichi M., and Mori T. Effect of epidermal growth factor on cadherin-mediated adhesion in human oesophageal cancer cell line. Br. J. Cancer 71 (1995) 250-258
154. Shoker B.S., Jarvis C., Davies M.P.A., Iqbal M., Sibson D.R., and Sloane J.P. Immunodetectable cyclin D-1 is associated with oestrogen receptor but not Ki67 in normal, cancerous and precancerous breast lesions. Br. J. Cancer 84 (2001) 1064-1069
155. Silvagno F., Guarnieri V., Capizzi A., and Pescarmona G.P. Synergistic effect of retinoic acid and dehydroepiandrosterone on differentiation of human neuroblastoma cells. FEBS Lett. 532 (2002) 153-158
156. Slominski A., Heasley D., Mazurkiewicz J.E., Ermak G., Baker J., and Carlson J.A. Expression of pro-opiomelanocortin (POMC)-derived melanocyte-stimulating hormone (MSH) and adrenocorticotropic hormone (ACTH) peptides in skin of basal cell carcinoma patients. Human Pathol. 30 (1999) 208-216
157. Soubeyran I., Wafflart J., Bonichon F., De Mascarel I., Trojani M., Durand M., Avril A., and Coindre J.M. Immunohistochemical determination of pS2 in invasive breast carcinomas: a study of 942 cases. Breast Cancer Res. Treat. 34 (1995) 119-128
158. Spiethoff A., Schenck A., and Bohrer M. Relationship of DNA ploidy to hormone receptor status and proliferation in invasive breast cancer. J. Cancer Res. Clin. Oncol. 126 (2000) 707-710
159. Srinivasan G., Campbell E., and Bashirelahi N. Androgen, oestrogen, and progesterone receptors in normal and ageing prostates. Microscopy Res. Technique 30 (1995) 293-304
160. Staibano S., Franco R., Mezza E., Chieffi P., Sinisi A., Pasquali D., Errico M.E., Nappi C., Tremolaterra F., Somma P., Mansueto G., and De Rosa G. Loss of oestrogen receptor beta, high PCNA and p53 expression and aneuploidy as markers of worse prognosis in ovarian granulosa cell tumours. Histopathology 43 (2003) 254-262
161. Stal O., Sullivan S., Sun X.F., Wingren S., and Nordenskojld B. Simultaneous analysis of c-erbB2 expression and DNA content in breast cancer using flow cytometry. Cytometry 16 (1994) 160-168
162. Stephan C., Vogel B., Cammann H., Lein M., Klevecka V., Sinha P., Kristiansen G., Schnorr D., Jung K., and Loening S.A. An artificial neural network as a tool in risk evaluation of prostate cancer. Indication for biopsy within the PSA range of 2-20 mu g/I. Urologie 42 (2003) 1221-1229
163. Strom A., Arai N., Leers J., and Gustafsson J.A. The hairy and enhancer of split homologue-1 (HES-1) mediates the proliferation effect of 17-β oestradiol on breast cancer cell lines. Oncogene 19 (2000) 5951-5953
164. Suarez C., Vizoso F., Rodriguez J.C., Garcia I., Raigoso P., Allende M.T., Garcia-Muniz J.L., and Garcia-Moran M. Prognostic significance of cytosolic pS2 protein content in gastric cancer. Int. J. Biol. Markers 16 (2001) 37-44
165. Sun X.F., Cartensen J.M., Stal O., Zhang H., and Nordenskjold B. C-erbB2 oncoprotein in relation to DNA ploidy and prognosis in colorectal adenocarcinoma. APMIS 103 (1995) 309-315
166. Sung V., Gilles C., Murray A., Clarke R., Aaron A.D., Azumi N., and Thompson E.W. The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype. Exp. Cell Res. 241 (1998) 273-284
167. Talvensaari-Mattila A., Paakko P., and Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br. J. Cancer 89 (2003) 1270-1275
168. Thompson E.W., Reich. R., Shima T.B., Albini A., Graf G., Martin G.R., Dickson R.B., and Lippman M.E. Differential regulation of growth and invasiveness of MCF7 breast cancer cells by anti-oestrogens. Cancer Res. 48 (1988) 6764-6768
169. Thompson E.V., Katz D., Shima T.B., Wakeling A.E., Lippman M.E., and Dickson R.B. ICI 164, 384 a pure antagonist of oestrogen-stimulated MCF7 cell proliferation. Cancer Res. 49 (1989) 6929-6939
170. Thompson J., Hyytinen E.R., Haapala K., Rantala I., Helin H.J., Janne O.A., Palvimo J.J., and Koivisto P.A. Androgen receptor mutations in high-grade prostate cancer before hormonal therapy. Lab. Invest. 83 (2003) 1709-1713
171. Thor A.D., Koerner F.C., Edgerton S.M., Wood W.C.C., Stracher M.A., and Schwartz L.H. pS2 expression in primary breast carcinoma: Relationship to clinical and biological features and survival. Breast Cancer Res. Treat. 21 (1992) 111-119
172. Thorpe S.M., Rose C., Rasmussen B.B., Mouridsen H.T., Bayer T., and Keiding N. Prognostic value of steroid hormone receptors: Multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res. 47 (1987) 6126-6133
173. Tsutsui S., Ohno S., Murakami S., Hachitanda Y., and Oda S. DNA aneuploidy in relation to the combination of analysis of oestrogen receptor, progesterone receptor, p53 protein and epidermal growth factor receptor in 498 breast cancers. Oncology 63 (2002) 48-55
174. Tuck A.B., Arsenault D.M., O'Malley F.P., Hota C., Ling M.C., Wilson S.M., and Chambers A.F. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18 (1999) 4237-4246
175. Tunuguntla R., Ripley D., Sang Q.X.A., and Chegini N. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and-4 in benign endometrium and endometrial cancer. Gynecol. Oncol. 89 (2003) 453-459
176. Tushaus L., Hopert A.C., Strunck E., Schubert C., Wunsche W., and Vollmer G. Estrogenic and anti-estrogenic regulation of MMP-2 and MMP-13 mRNA in RUCA-I endometrial tumour cells in vitro and in vivo. Cancer Lett. 198 (2003) 99-106
177. Ueoka Y., Kato K., and Wake N. Hepatocyte growth factor modulates motility and invasiveness of ovarian carcinoma via ras mediated pathway. Mol. Cell. Endocrinol. 202 (2003) 81-88
178. Valverde P., Healy E., Sikkink S., Haldane F., Thody A.J., Carothers A., Jackson I.J., and Rees J.L. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Human Mol. Genet. 5 (1996) 1663-1666
179. Wang M.H., MonteroJulian F.A., Dauny I., and Leonard E.J. Requirement of phosphatidylinositol-3 kinase for epithelial cell migration activated by human macrophage stimulating protein. Oncogene 13 (1996) 2167-2175
180. Wang D.G., Johnston. C.F., Liu W.H., Sloan J.M., and Buchanan K.D. Expression of a breast-cancer-associated protein (pS2) in human neuro-endocrine tumours. Int. J. Cancer 74 (1997) 270-274
181. Wang D.G., Liu W.H., Lundy F.T., Pogue K.M., Cunningham R.T., Johnston C.F., and Buchanan K.D. TFF1 gene expression in human medullary thyroid carcinoma. Pathology 184 (1998) 408-413
182. Watanabe T., Banno T., Jeziorowski T., Ohsawa Y., Waguri S., Grube D., and Uchiyama Y. Effects of sex steroids on secretory granule formation in gonadotropes of castrated male rats with respect to granin expression. Endocrinology 139 (1998) 2765-2773
183. Weber M.J., and Gioeli D. Ras signalling in prostate cancer progression. J. Cell. Biochem. 91 (2003) 13-25
184. Wenger C.R., Beardslee S., Owens M.A., Pounds G., Oldaker T., Vendely P., Pandian M.R., Harrington D., Clark G.M., and McGuire WL. DNA ploidy, S-phase and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res. Treat. 28 (1993) 9-20
185. Williams M.R., Todd J.H., Ellis I.O., Dowle C.S., Haybittle J.L., Elston C.W., Nicholson R.I., Griffiths K., and Blamey R.W. Oestrogen receptors in primary and advanced breast cancer: An eight year review of 704 cases. Br. J. Cancer 55 (1987) 67-73
186. Xuan J.W., Hota C., Shiegeyama Y., D'Erricod J.A., Somerman M.J., and Chambers A.F. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration. J. Cell. Biochem. 57 (1995) 680-690
187. Yamachika T., Werther J.L., Bodian C., Babyatsky M., Tatematsu M., Yamamura Y., Chen A.L., and Itzkowitz S. Intestinal trefoil factor: a marker of poor prognosis in gastric carcinoma. Clin. Cancer Res. 8 (2002) 1092-1099
188. Yamashita H., Nishio M., Toyama T., Sugiura H., Zhang Z., Kobayashi S., and Iwase H. Co-existence of HER-2 over-expression and p53 accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res. 6 (2004) R24-R30
189. Yang L., Yeh S.D., Xie S.Z., Altuwaijri S., Ni J., Hu Y.C., Chen Y.T., Bao B.Y., Su C.H., and Chang C.S. Androgen suppresses PML protein expression in prostate cancer CWR22R cells. Biochem. Biophys. Res. Commun. 314 (2004) 69-75
190. Yoshida R., Ohuchi N., and Kimura N. Clinicopathological study of chromogranin A, B and BRCA1 expression in node-negative breast carcinoma. Oncol. Rep. 9 (2002) 1363-1367
191. Yu C.L., Driggers P., Barrera-Hernandez G., Nunez S.B., Segars J.H., and Cheng S.Y. The tumour suppressor p53 is a negative regulator of oestrogen receptor signalling pathways. Biochem. Biophys. Res. Commun. 239 (1997) 617-620
192. Yuan J., Hennessy C., Givan A.L., Corbett I.P., Henry J.A., Sherbet G.V., and Lennard T.W.J. Predicting outcome for patients with node negative breast cancer. A comparative study of the value of flow cytometry and cell image analysis for determination of DNA ploidy. Br. J. Cancer 65 (1992) 461-465
193. Yue W., Wang J.P., Conaway M., Masamura S., Li Y.B., and Santen R.J. Activation of the MAPK pathway enhances sensitivity of MCF7 breast cancer cells to the mitogenic effect of oestradiol. Endocrinology 143 (2002) 3221-3229
194. Zhang Y.J., Wei L.H., Wang J.L., and Sun T.Z. Role of phosphatase PTEN in the activation of extracellular signal regulated kinase induced by oestradiol in endometrial carcinoma cells. Chinese Med. J. 116 (2003) 383-387
195. Zhu N.W., Eves P.C., Katerinaki E., Szabo M., Morandini R., Ghanem G., Lorigan P., MacNeil S., and Haycock J.W. Melanoma cell attachment, invasion, and integrin expression is up regulated by tumour necrosis factor alpha and suppressed by alpha melanocyte stimulating hormone. J. Invest. Dermatol. 119 (2002) 1165-1171
196. Zubair A., Lakshmi M.S., and Sherbet G.V. Expression of alpha melanocyte stimulating hormone and the invasive ability of the B16 murine melanoma. Anticancer Res. 12 (1992) 399-402